x

Posted 01 July, 2021

Cidara Therapeutics, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:CDTX in a 8-K filed on 01 July, 2021.


  Effective as of the date of Mr. Levine's resignation, Jeffrey L. Stein, President and Chief Executive Officer of the Company, will assume the role of the Company's principal financial officer, and Brady Johnson will be promoted to Vice President, Finance and assume the role of the Company's principal accounting officer.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Cidara Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Market Cap
$257M
View Company Details
Cidara Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 

Effective as of July 9, 2021, James Levine resigned from his position as the Chief Financial Officer, including as the principal financial officer and principal accounting officer, of Cidara Therapeutics, Inc. (the "Company"). Mr. Levine resigned from the Company in order to pursue other opportunities. 

Effective as of the date of Mr. Levine's resignation, Jeffrey L. Stein, President and Chief Executive Officer of the Company, will assume the role of the Company's principal financial officer, and Brady Johnson will be promoted to Vice President, Finance and assume the role of the Company's principal accounting officer. There will be no change to Dr. Stein's or Mr. Johnson's compensation arrangements with the Company as a result of their respective appointments. There are no family relationships between each of Dr. Stein and Mr. Johnson and any of the Company's current or former directors or executive officers. Neither Dr. Stein nor Mr. Johnson is a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933, as amended. 

Mr. Levine has agreed to serve as a consultant to the Company for at least the six month period following his resignation to assist with a smooth transition of his duties, and his Company equity awards will continue to vest during such period of transition services.